Continuing Education  » Oncology  » New Insights on Canine Hemangiosarcoma and Overcoming Misinformed Recommendations for E...

New Insights on Canine Hemangiosarcoma and Overcoming Misinformed Recommendations for Euthanasia

CE Event Information

  • Description:
    Information derived from retrospective studies over the years has led to a common belief that splenic hemangiosarcoma in dogs is a malignant and aggressive type of cancer with a poor long term prognosis. Based on this information and other anecdotes, many animals that present with hemoabdomen associated with a splenic mass are euthanized.

    A revolutionary push to learn more about splenic mass rupture and canine hemangiosarcoma has been undertaken by Ethos Discovery. Utilizing molecular medicine, veterinary scientists are seeing that, in fact, benign pathologies are much more common than once believed. As such, veterinarians may be providing a misinformed recommendation of euthanasia for these dogs.

    In this segment, Dr. Chand Khanna - a veterinary cancer expert - joins us to discuss some of the exciting findings coming from an ongoing nationwide, prospective study of dogs with hemangiosarcoma. This new information, along with ongoing work to develop therapeutics to treat canine hemangiosarcoma, may soon result in curative outcomes for dogs with hemangiosarcoma.

    Fee:  $20 or FREE for VetVine Premium Membership subscribers



  • Date: October 24, 2023
  • Time: 12:00 PM US/Eastern
  • Sponsor: VetVine, Ethos Discovery
  • Presenter(s): Chand Khanna, DVM, PhD, DACVIM (Oncology), DACVP (Hon)
  • Fee (Basic Membership): $20